Beleaguered genetic testing company 23andMe announced Friday that it has reached an agreement to sell itself to a nonprofit led by the company’s co-founder and former CEO Anne Wojcicki. Following a massive cyberattack in 2023 and a related lawsuit settlement, 23andMe filed for bankruptcy in March, with Wojcicki resigning in order to become an independent […]
Anne Wojcicki’s nonprofit reaches deal to acquire 23andMe Read More »
DNA testing service 23andMe filed for bankruptcy protection in March, sparking concerns about what could happen to the genetic data of the company’s 15 million customers. Pharmaceutical giant Regeneron announced in May that it was buying the genetic testing company for $256 million following a bankruptcy auction. While the company has said it will maintain 23andMe’s
How to delete your 23andMe data Read More »
23andMe’s interim chief executive Joseph Selsavage told lawmakers on Tuesday that 1.9 million people, or about 15% of its customer base, have requested their genetic data be deleted from the company’s servers since it filed for bankruptcy protection in March. Selsavage was speaking at a House Oversight Committee hearing, during which lawmakers scrutinized the company’s
23andMe says 15% of customers asked to delete their genetic data since bankruptcy Read More »
Vijay Pande, a general partner at Andreessen Horowitz who founded the firm’s a16z Bio + Health strategy, announced that he is stepping down from his role. Since its founding in 2014, a16z Bio + Health has raised four funds of nearly $3 billion each, including a $1.5 billion fund that closed in 2022. However, it’s
Vijay Pande, founding partner of a16z bio and health strategy, steps down Read More »
The IPO market is starting to feel healthier. Omada Health, a 14-year-old company providing virtual care for chronic conditions like diabetes and hypertension between office visits, closed its first trading day on Friday at $23 a share, a 21% jump from the IPO price of $19. The IPO valued the company just above $1 billion
Omada Health IPO signals healthier market, avoids ‘down-round’ trend Read More »
Ben Lamm, the billionaire founder of Colossal Labs, and Sophie Turner spoke about his company’s efforts in reviving the long-extinct dire wolf during a panel at SXSW’s first London outpost. The wolf re-entered the public consciousness because of the television show “Game of Thrones,” in which Turner was a leading character. It turns out that
Samsung’s venture investment unit is looking to invest in California-based medical device startup, Exo, in a round that could climb to $100 million, Bloomberg reported, citing anonymous sources. The round is being led by Sands Capital, Bold Capital and Qubit Health Capital, the report said, adding that Qubit’s chairman, Imar Ishrak, would join Exo’s board.
Samsung may invest in $100M round for medical imaging startup Exo Read More »
Hinge Health, a digital physical therapist company, closed its first day of trading on the New York Stock Exchange on Thursday at $37.56, up about 17% over the $32 IPO price it set the previous day. That’s a good first-day result. But even with the pop, Hinge’s public valuation is significantly less than its last
Hinge Health pops 17%, but joins growing ranks of down round IPOs Read More »
Here’s the deal: Only 4 days left to save up to $900 on your TechCrunch Disrupt 2025 ticket — and an additional 90% off for your +1. From October 27–29, San Francisco’s Moscone West transforms into the epicenter of tech innovation as 10,000 tech, startup, and VC leaders gather for the 20th anniversary of TechCrunch
Up to $900 off your ticket and 90% off for your +1 at Disrupt 2025 Read More »
Pharmaceutical maker Regeneron announced Monday it will buy genetic testing company 23andMe for $256 million following a bankruptcy auction. Regeneron said it will acquire 23andMe’s genomics service and its bank of 15 million customers’ personal and genetic data as part of the deal. The pharma giant said it plans to use the 23andMe customer data
Pharma giant Regeneron to buy 23andMe and its customers’ data for $256M Read More »
